مكافحة | الموقت

العد التنازلي | مكافحة | الموقت !

  • Glymab® - Scancell
    Scancell has developed the GlyMab® platform to generate a series of high affinity tumour specific monoclonal antibodies (mAb) targeting glycans that are over-expressed on cancer cells
  • Antibody glycosylation in inflammation, disease and vaccination
    Therefore comparison of antibody responses against the same antigen in the context of infection or vaccination may result in highly different glycan profiles Similarly, treatment of inflammatory flares in autoimmune diseases may significantly alter the glycan repertoire irrespective of antigen specificity
  • Glycan masking in vaccine design: Targets, immunogens and . . . - Frontiers
    A third limitation in immunogen design through glycan masking is the availability of structural information Knowledge on the overall atomic structure of the antigen is recommended to successfully identify potential glycosylation sites on the protein surface, and thus avoid misfolding
  • A leader in antibody and vaccine oncology platforms
    Scancell is a clinical stage immunology specialist It has two promising oncology vaccine platforms, Moditope and ImmunoBody, and two antibody technologies, GlyMab (anti-glycans) and AvidiMab, with the potential to treat many solid cancers, either as monotherapy or in combination
  • Isolation and characterization of IgG3 glycan-targeting antibodies with . . .
    Author summary Antibodies typically recognize antigen with high specificity, thus targeting a single pathogen We used LIBRA-seq to identify a class of glycan-targeting human IgG3 antibodies with antigen specificities that span multiple viral families including influenza HA, HIV-1 Env, and SARS-CoV-2 spike, while simultaneously displaying no measurable autoreactivity to human proteins One of
  • Serum antibody screening using glycan arrays - RSC Publishing
    In addition, glycan microarrays enable detailed analysis of the immune system's response to vaccines and other treatments Herein we review applications of glycan microarray technology for serum anti-glycan antibody profiling
  • Glycan masking in vaccine design: Targets, immunogens and applications
    In this review, we will give an overview of the state-of-the-art in glycan masking, highlighting successes and limitations of this technique We will describe the pathogens and antigens considered for epitope focused immunogen design and the vector systems used for enhancement of the immune response
  • Scancell Holdings plc Scancell progresses its new anti-glycan . . .
    Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, provides an update on its anti-glycan monoclonal antibody (mAb) platform, now branded GlyMabTM The Company’s fourth proprietary platform has the potential to expand further its pipeline of novel anti-cancer mAbs and the versatility to yield other drug formats
















العد التنازلي | مكافحة | الموقت ©2005-2009
| Currency Exchange Rate |為替レート |Währungsrechner |gold price widget |oil price widget